| Date | Time | Source | Headline | Symbol | Company |
| 24/01/2019 | 13:08 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:APRI | Apricus Biosciences, Inc. |
| 24/01/2019 | 13:06 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:APRI | Apricus Biosciences, Inc. |
| 24/01/2019 | 13:01 | GlobeNewswire Inc. | Seelos Therapeutics, Inc. Announces Successful Completion of its Merger with Apricus Biosciences, Inc. to Advance Late-Stage ... | NASDAQ:APRI | Apricus Biosciences, Inc. |
| 24/01/2019 | 11:07 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:APRI | Apricus Biosciences, Inc. |
| 24/01/2019 | 11:06 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:APRI | Apricus Biosciences, Inc. |
| 16/01/2019 | 22:32 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:APRI | Apricus Biosciences, Inc. |
| 16/01/2019 | 22:30 | Edgar (US Regulatory) | Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) | NASDAQ:APRI | Apricus Biosciences, Inc. |
| 15/01/2019 | 12:00 | GlobeNewswire Inc. | Apricus Biosciences Stockholders Approve Proposed Merger with Seelos Therapeutics, Inc. | NASDAQ:APRI | Apricus Biosciences, Inc. |
| 04/01/2019 | 23:05 | Edgar (US Regulatory) | Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) | NASDAQ:APRI | Apricus Biosciences, Inc. |
| 04/01/2019 | 22:58 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:APRI | Apricus Biosciences, Inc. |
| 04/01/2019 | 17:08 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | NASDAQ:APRI | Apricus Biosciences, Inc. |
| 26/12/2018 | 21:12 | Edgar (US Regulatory) | Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) | NASDAQ:APRI | Apricus Biosciences, Inc. |
| 17/12/2018 | 11:15 | Edgar (US Regulatory) | Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) | NASDAQ:APRI | Apricus Biosciences, Inc. |
| 17/12/2018 | 11:15 | Edgar (US Regulatory) | Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) | NASDAQ:APRI | Apricus Biosciences, Inc. |
| 17/12/2018 | 11:10 | Edgar (US Regulatory) | Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) | NASDAQ:APRI | Apricus Biosciences, Inc. |
| 14/12/2018 | 21:49 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:APRI | Apricus Biosciences, Inc. |
| 14/12/2018 | 21:47 | Edgar (US Regulatory) | Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) | NASDAQ:APRI | Apricus Biosciences, Inc. |
| 14/12/2018 | 17:30 | GlobeNewswire Inc. | Apricus Biosciences Adjourns Special Meeting of Stockholders to New Date | NASDAQ:APRI | Apricus Biosciences, Inc. |
| 10/12/2018 | 12:00 | GlobeNewswire Inc. | Apricus Biosciences Reminds Shareholders to Vote Before the Special Meeting on December 14, 2018 | NASDAQ:APRI | Apricus Biosciences, Inc. |
| 06/12/2018 | 13:08 | Edgar (US Regulatory) | Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) | NASDAQ:APRI | Apricus Biosciences, Inc. |
| 30/11/2018 | 13:02 | Edgar (US Regulatory) | Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) | NASDAQ:APRI | Apricus Biosciences, Inc. |
| 21/11/2018 | 11:01 | Edgar (US Regulatory) | Notice of Effectiveness (effect) | NASDAQ:APRI | Apricus Biosciences, Inc. |
| 20/11/2018 | 22:23 | Edgar (US Regulatory) | Confidential Treatment Order (ct Order) | NASDAQ:APRI | Apricus Biosciences, Inc. |
| 20/11/2018 | 21:11 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) | NASDAQ:APRI | Apricus Biosciences, Inc. |
| 16/11/2018 | 22:33 | Edgar (US Regulatory) | Registration Statement for Securities to Be Issued in Business Combination Transactions (s-4/a) | NASDAQ:APRI | Apricus Biosciences, Inc. |
| 16/11/2018 | 21:16 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:APRI | Apricus Biosciences, Inc. |
| 16/11/2018 | 21:15 | Edgar (US Regulatory) | Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) | NASDAQ:APRI | Apricus Biosciences, Inc. |
| 31/10/2018 | 20:37 | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:APRI | Apricus Biosciences, Inc. |
| 31/10/2018 | 20:36 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:APRI | Apricus Biosciences, Inc. |
| 31/10/2018 | 20:24 | GlobeNewswire Inc. | Apricus Biosciences Provides Corporate Update and Third Quarter 2018 Financial Results | NASDAQ:APRI | Apricus Biosciences, Inc. |